This post-hoc study looked at the influence of continuous inhalation treprostinil medication on the occurrence and severity of numerous disease progression events. The INCREASE trial of inhaled treprostinil, a change in 6-minute walk distance, was fulfilled at Week 16. Furthermore, individuals receiving inhaled treprostinil saw considerably fewer clinical deterioration occurrences. The frequency of several incidents in the same patient, on the other hand, remained unknown. During the 16-week study, patients enrolled in INCREASE were monitored for disease progression events, defined as a greater than or equal to 15% decline in 6-minute walk distance, exacerbation of underlying lung disease, cardiopulmonary hospitalization, lung transplantation, greater than or equal to 10% declined in forced vital capacity, or death. The inhaled treprostinil group had 147 disease progression events (89/163 patients, 55%) compared to 215 occurrences (109/163 patients, 67%) in the placebo group (P=0.018). The inhaled treprostinil group had a decreased rate of 6-minute walk distance reduction (45 vs. 64 events), lung disease exacerbation (48 vs. 72 events), forced vital capacity loss (19 vs. 33), cardiopulmonary hospitalization (23 vs. 33 events), and death (23 vs. 33 events) (10 vs. 12).
Compared to placebo, patients who received inhaled treprostinil experienced fewer progression events (35 vs. 58; 22% vs. 36%, P=0.005). Inhaled treprostinil patients were considerably less likely to encounter subsequent illness progression after an initial incident than placebo. Despite the frequency of disease progression in clinical practice, the findings justify the use of inhaled treprostinil.
Reference:www.atsjournals.org/doi/abs/10.1164/rccm.202107-1766OC
